Expression and clinical significance of CN-Ⅱ in non-small cell lung cancer tissues
10.3969/j.issn.1000-8179.20141672
- VernacularTitle:胞浆-5'-核苷酸酶-Ⅱ在非小细胞肺癌组织中的表达及其临床意义
- Author:
Lili QU
;
Xiaoqing LIU
;
Weixia WANG
;
Chuanhao TANG
;
Jianjie LI
;
Xiaoyan LI
;
Hongjun GAO
;
Xiaobing LI
;
Guangxian LIU
- Publication Type:Journal Article
- Keywords:
cytosolic 5'-nucleotidase;
gemcitabine;
resistance;
non-small cell lung cancer
- From:
Chinese Journal of Clinical Oncology
2015;(1):56-60
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Cytosolic 5'-nucleotidase (CN-Ⅱ), a nucleotide kinase, exhibits both 5'-nucleotidase and nucleoside phos-photransferase activities. Abnormal CN-Ⅱexpression may be correlated with the resistance of nucleoside analogs in anticancer drugs. This study was designed to investigate CN-Ⅱexpression in human non-small cell lung cancer (NSCLC) tissues and its correlation with the clinicopathological parameters as well as the prognosis of patients treated with gemcitabine. Methods:Immunohistochemistry was used to detect CN-Ⅱexpression in 116 cases of paraffin-embedded NSCLC samples. The correlations with the clinicopathological pa-rameters and the response to gemcitabine chemotherapy of CN-Ⅱwere analyzed through the Chi-square test. Log-rank test was used to determine whether or not CN-Ⅱexpression is correlated with the overall survival of patients. Results:The positive rate of CN-Ⅱwas 53.4% in 116 NSCLC tissues. No significant correlation existed between CN-Ⅱ expression and the clinicopathological parameters. Among the 67 of the 116 patients who received gemcitabine chemotherapy, those with tumor progression (positive rate of 57.6%) exhib-ited higher CN-Ⅱexpression than those with therapeutic efficacy (positive rate of 30.4%, P=0.008) and disease-control chemotherapy (positive rate of 36.7%, P=0.013). The progression-free survival was 4.5 and 5.5 months in the CN-Ⅱ-positive and CN-II-negative groups, respectively, with significant differences (95%CI:4.452 to 6.148, P=0.041). Correspondingly, the overall survival was 9.5 and 11.0 months in the two groups (95%CI:8.667 to 13.333, P=0.282). Conclusion:CN-Ⅱmay be a prognostic factor for gemcitabine chemotherapy in NSCLC patients.
